Video

Results of a Combined Modality Screening Approach in Women Without Cancer History

Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.

Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.

In the trial, investigators evaluated the benefit of using the DETECT-A blood test combined with standard-of-care screening in 10,006 women without a history of cancer. Individuals with positive DETECT-A blood test results also underwent PET-CT to identify the potential cancer.

The results demonstrated that the combined modality approach doubled the number of cancers that were detected with screening. The blood test identified 10 different cancer types, including 7 for which there is currently no screening test available. Moreover, the blood test had positive predictive value that superseded current noninvasive screening tests for individual cancers. Of the cancers that were identified with the blood test, 65% were localized or regional, suggesting that the combined modality approach could lead to more curative intent interventions.

<<< 2020 AACR Annual Meeting

Related Videos
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Sonali M. Smith, MD
Sergio A. Giralt, MD
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lyudmila A. Bazhenova, MD, clinical professor, medicine, The University of California, San Diego (UCSD); medical oncologist, Moores Cancer Center, UCSD Health
Narjust Florez, MD, associate director, Cancer Care Equity Program, Dana-Farber Brigham Cancer Center; physician, Dana-Farber Cancer Institute; member, faculty, Harvard Medical School
Jonathan Wesley Riess, MD, MS, director, Thoracic Oncology, associate professor, medicine, Division of Hematology and Oncology, University of California, Davis Comprehensive Cancer Center
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine